Author | Ruth M. O'Regan, MD


How to Improve Adjuvant Therapy in HER2-Positive Breast Cancer

January 10, 2018

This video reviews various trials that aimed to improve outcomes or minimize toxicities among patients receiving adjuvant treatment for HER2-positive breast cancer.

Genomic Subtypes in Choosing Adjuvant Therapy for Breast Cancer

March 15, 2013

Additional insight into the biology of ER-positive breast cancers, particularly the higher risk luminal B cancers, could aid in identifying potential targets and new, effective therapies. And though the majority of triple-negative breast cancers are the “basal-like” subtype, significant proportions are in other subtypes.

Adjuvant Anthracyclines: Time for a Change of Heart?

February 18, 2011

As our knowledge of the molecular profiles of breast cancer has increased as a result of moving closer to our goal of individualized therapy, it is clear that we need to re-think our approach to the adjuvant treatment of early-stage breast cancer.

Long-Term Toxicities of Selective Estrogen-Receptor Modulators and Antiaromatase Agents

May 01, 2003

With the advent of aromataseinhibitor use in the adjuvantsetting,[1] and the inceptionof trials examining their usefor breast cancer prevention, it seemsprudent to evaluate what we know todate about the long-term effects of these agents. Unfortunately, unlike selectiveestrogen-receptor modulators(SERMs)-in particular tamoxifen,[2]which has been used for over 15 yearsin patients with early-stage breast cancer-long-term data on the use of aromataseinhibitors are minimal.